GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Urologix Inc (OTCPK:ULGX) » Definitions » Asset Turnover

Urologix (Urologix) Asset Turnover : 0.54 (As of Mar. 2015)


View and export this data going back to 1996. Start your Free Trial

What is Urologix Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Urologix's Revenue for the three months ended in Mar. 2015 was $2.80 Mil. Urologix's Total Assets for the quarter that ended in Mar. 2015 was $5.17 Mil. Therefore, Urologix's Asset Turnover for the quarter that ended in Mar. 2015 was 0.54.

Asset Turnover is linked to ROE % through Du Pont Formula. Urologix's annualized ROE % for the quarter that ended in Mar. 2015 was 17.67%. It is also linked to ROA % through Du Pont Formula. Urologix's annualized ROA % for the quarter that ended in Mar. 2015 was -26.99%.


Urologix Asset Turnover Historical Data

The historical data trend for Urologix's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Urologix Asset Turnover Chart

Urologix Annual Data
Trend Jun05 Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.32 1.48 1.75 1.32 1.57

Urologix Quarterly Data
Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.44 0.54 0.57 0.54

Competitive Comparison of Urologix's Asset Turnover

For the Medical Devices subindustry, Urologix's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Urologix's Asset Turnover Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Urologix's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Urologix's Asset Turnover falls into.



Urologix Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Urologix's Asset Turnover for the fiscal year that ended in Jun. 2014 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Jun. 2014 )/( (Total Assets (A: Jun. 2013 )+Total Assets (A: Jun. 2014 ))/ count )
=14.235/( (12.527+5.667)/ 2 )
=14.235/9.097
=1.56

Urologix's Asset Turnover for the quarter that ended in Mar. 2015 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2015 )/( (Total Assets (Q: Dec. 2014 )+Total Assets (Q: Mar. 2015 ))/ count )
=2.796/( (5.321+5.023)/ 2 )
=2.796/5.172
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Urologix  (OTCPK:ULGX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Urologix's annulized ROE % for the quarter that ended in Mar. 2015 is

ROE %**(Q: Mar. 2015 )
=Net Income/Total Stockholders Equity
=-1.396/-7.8985
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1.396 / 11.184)*(11.184 / 5.172)*(5.172/ -7.8985)
=Net Margin %*Asset Turnover*Equity Multiplier
=-12.48 %*2.1624*-0.6548
=ROA %*Equity Multiplier
=-26.99 %*-0.6548
=17.67 %

Note: The Net Income data used here is four times the quarterly (Mar. 2015) net income data. The Revenue data used here is four times the quarterly (Mar. 2015) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Urologix's annulized ROA % for the quarter that ended in Mar. 2015 is

ROA %(Q: Mar. 2015 )
=Net Income/Total Assets
=-1.396/5.172
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-1.396 / 11.184)*(11.184 / 5.172)
=Net Margin %*Asset Turnover
=-12.48 %*2.1624
=-26.99 %

Note: The Net Income data used here is four times the quarterly (Mar. 2015) net income data. The Revenue data used here is four times the quarterly (Mar. 2015) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Urologix Asset Turnover Related Terms

Thank you for viewing the detailed overview of Urologix's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Urologix (Urologix) Business Description

Traded in Other Exchanges
N/A
Address
14405 21st Avenue North, Suite 110, Minneapolis, MN, USA, 55447
Urologix Inc is a United States-based company engaged in the development, manufacturing, and marketing of minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The firm markets the Cooled ThermoTherapy (CTC) product line and the Prostiva Radio Frequency (RF) Therapy System (Prostiva). The CTC produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. The CTC product line includes the CoolWave and Targis Control Units and the CTC Advance catheter.
Executives
Emery Sidney W Jr director C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Patrick D Spangler director 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Gregory Fluet director, officer: CEO 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
William M Moore director
Guy C Jackson director C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Daniel J Starks director ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Claude Tihon officer: Chief Technology Officer
Bobby Ivan Griffin director 1326 SPRING VALLEY RD GOLDEN VALLEY PA 55422
David A Montecalvo officer: VP, Product Dev. & Operations 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Susan Bartlett Foote director 649 SUMMIT AVENUE, ST PAUL MN 55105

Urologix (Urologix) Headlines

From GuruFocus

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 3,100 Shares

By GuruFocus Research GuruFocus Editor 12-07-2009

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 5,200 Shares

By GuruFocus Research GuruFocus Editor 02-01-2011

Urologix Inc. Reports Operating Results (10-K)

By gurufocus 10qk 09-21-2009

Urologix Inc. Reports Operating Results (10-K)

By gurufocus 10qk 09-17-2010

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 16,900 Shares

By GuruFocus Research GuruFocus Editor 12-09-2009